A share price of Vertex Pharmaceuticals, Inc. [VRTX] is currently trading at $397.36, up 0.20%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRTX shares have lost -1.70% over the last week, with a monthly amount drifted -2.79%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] stock has seen the most recent analyst activity on April 11, 2024, when Evercore ISI upgraded its rating to a Outperform but kept the price target unchanged to $438 for it. Previously, Wolfe Research started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $515. On February 06, 2024, downgrade downgraded it’s rating to In-line and revised its price target to $438 on the stock. Bernstein downgraded its rating to a Mkt Perform. Robert W. Baird downgraded its rating to a Underperform but $325 remained the price target by the analyst firm on January 31, 2024. Maxim Group downgraded its rating to Hold for this stock on January 31, 2024. In a note dated January 24, 2024, Canaccord Genuity downgraded an Sell rating on this stock and boosted its target price from $332 to $379.
Vertex Pharmaceuticals, Inc. experienced fluctuations in its stock price throughout the past year between $316.43 and $448.40. Currently, Wall Street analysts expect the stock to reach $309.89 within the next 12 months. Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] shares were valued at $397.36 at the most recent close of the market. An investor can expect a potential drop of -22.01% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Trailing Twelve Months sales for Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] were 9.84B which represents 12.00% growth. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.39%, Pretax Profit Margin comes in at 0.44%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.23 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 395.20 points at the first support level, and at 393.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 401.00, and for the 2nd resistance point, it is at 404.64.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] is 3.99. On the other hand, the Quick Ratio is 3.78, and the Cash Ratio is 2.92. Considering the valuation of this stock, the price to sales ratio is 10.43, the price to book ratio is 5.82 and price to earnings (TTM) ratio is 28.61.
Transactions by insiders
Recent insider trading involved Ambrose Kristen, SVP & Chief Accounting Officer, that happened on Apr 02 ’24 when 240.0 shares were sold. EVP, COO, Arbuckle Stuart A completed a deal on Feb 26 ’24 to sell 5034.0 shares. Meanwhile, EVP, Global Research and CSO ALTSHULER DAVID sold 4239.0 shares on Feb 26 ’24.
